Extent of FLAIR Hyperintense Vessels May Modify Treatment Effect of Thrombolysis: A Post hoc Analysis of the WAKE-UP Trial

Anne Sophie Grosch; Anna Kufner; Florent Boutitie; Bastian Cheng; Martin Ebinger; Matthias Endres; Jochen B Fiebach; Jens Fiehler; Alina Koenigsberg; Robin Lemmens; Keith W Muir; Norbert Nighoghossian; Salvador Pedraza; Claus Z Siemonsen; Vincent Thijs; Anke Wouters; Christian Gerloff; Goetz Thomalla; Ivana Galinovic

Journal article

Extent of FLAIR Hyperintense Vessels May Modify Treatment Effect of Thrombolysis: A Post hoc Analysis of the WAKE-UP Trial

Anne Sophie Grosch, Anna Kufner, Florent Boutitie, Bastian Cheng, Martin Ebinger, Matthias Endres, Jochen B Fiebach, Jens Fiehler, Alina Koenigsberg, Robin Lemmens, Keith W Muir, Norbert Nighoghossian, Salvador Pedraza, Claus Z Siemonsen, Vincent Thijs, Anke Wouters, Christian Gerloff, Goetz Thomalla, Ivana Galinovic

Frontiers in Neurology | FRONTIERS MEDIA SA | Published : 2021

DOI: 10.3389/fneur.2020.623881

Abstract

Background and Aims: Fluid-attenuated inversion recovery (FLAIR) hyperintense vessels (FHVs) on MRI are a radiological marker of vessel occlusion and indirect sign of collateral circulation. However, the clinical relevance is uncertain. We explored whether the extent of FHVs is associated with outcome and how FHVs modify treatment effect of thrombolysis in a subgroup of patients with confirmed unilateral vessel occlusion from the randomized controlled WAKE-UP trial. Methods: One hundred sixty-five patients were analyzed. Two blinded raters independently assessed the presence and extent of FHVs (defined as the number of slices with visible FHV multiplied by FLAIR slice thickness). Patients we..

View full abstract

University of Melbourne Researchers

Vincent Thijs Author Florey Department of Neuroscience and Mental Health

Grants

Awarded by DFG under Germany's Excellence Strategy

Awarded by European Union Seventh Framework Program

Funding Acknowledgements

MEn received funding from DFG under Germany's Excellence Strategy-EXC-2049-390688087, BMBF, DZNE, DZHK, EU, Corona Foundation, and Fondation Leducq. The main clinical trial, WAKE-UP, was funded by a grant fromthe European Union Seventh Framework Program (278276). AKu is a participant in the BIH-Charite Junior Clinical Scientist Program funded by the Charite-Universitatsmedizin Berlin and the Berlin Institute of Health. We acknowledge support from the German Research Foundation (DFG) and the Open Access Publication Fund of Charite-Universitatsmedizin Berlin. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.